Pyrrole derivatives as P2Y12 antagonists

US7910576B2 · kind B2 · utility

Assignee

• Sanofi-Aventis · FR

Inventors

• Otmar Klingler · Rodgau, DE
• Joerg Czech · Marburg, DE
• Werngard Czechtizky · Frankfurt, DE
• Tilo Weiss · Frankfurt am Main, DE
• Melitta Just · Langen, DE

Key dates

• Filing date: Dec 16, 2009
• Grant date: Mar 22, 2011
• Expiry date: Dec 16, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of the formula I,in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.